⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 13, 2024The Journal of Clinical Endocrinology & MetabolismOpen Access

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer

Wei Zhang Shuhuang Lin Zhuo Wang Wenyong Zhang Mingzhao Xing

View Full Paper

Ask AI

Bookmark

Share

Abstract

The role of RET/PTC rearrangement in the clinical outcomes of papillary thyroid cancer (PTC) is controversial and remains to be clearly undefined.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e6a4f8b6db6435876282b3 https://doi.org/10.1210/clinem/dgae327

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinicopathological Characteristics and Prognostic Significance of <scp>RET</scp> Fusion in Papillary Thyroid CarcinomaCohort Study · 2026
2<i>TERT</i> Promoter Mutations Increase Tumor Aggressiveness by Altering <i>TERT</i> mRNA Splicing in Papillary Thyroid Carcinoma2024 · 5 citations
3<i>TERT</i> mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer2024 · 14 citations
4Targeting RET in medullary thyroid cancer2025 · 3 citations
5Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma modelOriginal Research · 2006 · 73 citations